AURA: aurabiosciences.com Price/Earnings to Growth Multiple

Symbol and logo of brand Aura Corp (AURA)

The development of targeted therapy based on virus-like particles ensures business stability, which is confirmed by the undervalued "rockets" filter based on PEG. Patent protection for oncology biologics guarantees long-term profits, while FDA-supported laser eye treatments accelerate base growth for Aura Biosciences, Inc. (AURA). The value of 0.00 denotes the current metric, helping to determine the asset's real resilience and avoid buying at the peak.

Price/Earnings to Growth Ratio: Aura Biosciences Inc (AURA) for 07/04/2022 - 11/18/2026

Analytical breakdowns for aurabiosciences.com (AURA)

- share price and consensus valuation forecast:
Summary company analytics:AURA Aura Corp
Mass-produced product of Aura Biosciences, Inc.

Aura Biosciences, Inc. (AURA) is establishing a unique monopoly in ophthalmologic oncology by utilizing innovative VDC light-activated conjugates to destroy tumors without compromising vision. An analysis of the growth-adjusted P/E allows for a comparison of the market multiple with the dynamics of business expansion: values below one signal an undervaluation of the company's potential, while sharp deviations indicate either an investment opportunity or technological risks.

Competitors of Aura Biosciences, Inc.

Price/Earnings to Growth Multiple BeiGene Ltd ONC|PEG Multiple HALO (halozyme.com)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen (URGN) - Price/Earnings to Growth Ratio|Bicara Bio - Growth-Adjusted Payback Ratio|PSNL (Personalis Inc) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca, Inc. ERAS|PEG Multiple DCTH|YMAB - Price to Earnings Adjusted for Growth Rate|PEG Multiple CADL (Candel Therapeutics Inc.)|ARAY - Price/Earnings to Growth Multiple|SLS - Price/Earnings to Growth Ratio|Actuate Therapeutics - Company Value to Earnings Growth Ratio|CTOR: PEG Multiple|TuHURA (HURA) - PEG Multiple|TARA (Protara Therapeutics Inc) - PEG Multiple|FATE: Growth-Adjusted Payback Ratio|PEG Multiple WHWK|TCRX (TScan) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Champions Oncology, Inc. CSBR|XBIT - Price/Earnings to Growth Multiple|CEL-SCI - PEG Multiple|OSTX - PEG Multiple|Radiopharm Theranostics Limited (RADX) - Price/Earnings to Growth Ratio|ARTV - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ANL|Price/Earnings to Growth Ratio VERU|PEG Multiple TPST|XLO: Market Cap to Earnings and Growth Ratio|PEG Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Price to Earnings Adjusted for Growth Rate|Kairos Pharma Ltd - PEG Multiple|Market Cap to Earnings and Growth Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Price/Earnings to Growth Ratio|CRIS - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple APLM|Tharimmune (THAR) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc.)|Genprex - Growth-Adjusted P/E Ratio|PEG Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Price/Earnings to Growth Multiple|Xenetic Bio - PEG Multiple|SLRX - PEG Multiple|PPBT: PEG Multiple|Growth-Adjusted P/E Ratio AONC|BGNE (BeiGene Ltd) - PEG Multiple|CKPT (Checkpoint Therapeutics, Inc) - Company Value to Earnings Growth Ratio|PEG Multiple ELEV|Price/Earnings to Growth Multiple iCAD Corp ICAD|Price/Earnings to Growth Ratio ikenaoncology.com IKNA|NTBL - Price/Earnings to Growth Multiple|VIRX - Price/Earnings to Growth Ratio|MOR - PEG Multiple|NAYA: PEG Multiple|Ascentage Pharma Group (AAPGV) - PEG Multiple